Vontobel Holding Ltd. trimmed its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 793,597 shares of the medical research company's stock after selling 27,364 shares during the quarter. Thermo Fisher Scientific comprises 1.6% of Vontobel Holding Ltd.'s portfolio, making the stock its 15th largest position. Vontobel Holding Ltd. owned about 0.21% of Thermo Fisher Scientific worth $490,895,000 as of its most recent filing with the SEC.
Other institutional investors also recently bought and sold shares of the company. Beaumont Financial Advisors LLC boosted its holdings in Thermo Fisher Scientific by 0.8% in the 1st quarter. Beaumont Financial Advisors LLC now owns 2,199 shares of the medical research company's stock valued at $1,278,000 after purchasing an additional 17 shares during the last quarter. Cedar Wealth Management LLC grew its stake in Thermo Fisher Scientific by 14.5% during the 1st quarter. Cedar Wealth Management LLC now owns 134 shares of the medical research company's stock worth $78,000 after purchasing an additional 17 shares in the last quarter. Lafayette Investments Inc. increased its position in shares of Thermo Fisher Scientific by 2.1% in the 2nd quarter. Lafayette Investments Inc. now owns 830 shares of the medical research company's stock valued at $459,000 after purchasing an additional 17 shares during the last quarter. Patrick M Sweeney & Associates Inc. increased its stake in Thermo Fisher Scientific by 1.8% in the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,031 shares of the medical research company's stock valued at $570,000 after purchasing an additional 18 shares during the last quarter. Finally, Drive Wealth Management LLC boosted its position in shares of Thermo Fisher Scientific by 0.9% in the 2nd quarter. Drive Wealth Management LLC now owns 2,123 shares of the medical research company's stock valued at $1,175,000 after purchasing an additional 18 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at Thermo Fisher Scientific
In other news, VP Lisa P. Britt sold 3,624 shares of the business's stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $613.02, for a total value of $2,221,584.48. Following the transaction, the vice president now owns 13,699 shares in the company, valued at $8,397,760.98. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, VP Lisa P. Britt sold 3,624 shares of the stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $613.02, for a total transaction of $2,221,584.48. Following the sale, the vice president now owns 13,699 shares of the company's stock, valued at approximately $8,397,760.98. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 26th. The shares were sold at an average price of $600.85, for a total value of $1,201,700.00. Following the sale, the senior vice president now directly owns 13,083 shares of the company's stock, valued at $7,860,920.55. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 23,084 shares of company stock valued at $14,094,292 in the last 90 days. 0.34% of the stock is currently owned by corporate insiders.
Thermo Fisher Scientific Stock Performance
Shares of Thermo Fisher Scientific stock traded down $8.97 on Wednesday, hitting $591.55. The stock had a trading volume of 1,367,498 shares, compared to its average volume of 1,466,425. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $627.88. The stock has a market cap of $225.80 billion, a price-to-earnings ratio of 38.52, a price-to-earnings-growth ratio of 3.80 and a beta of 0.77. The business's 50 day moving average is $607.81 and its two-hundred day moving average is $583.76. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, beating the consensus estimate of $5.13 by $0.24. The business had revenue of $10.54 billion for the quarter, compared to analyst estimates of $10.50 billion. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. Thermo Fisher Scientific's revenue was down 1.4% compared to the same quarter last year. During the same period last year, the firm posted $5.15 earnings per share. Analysts forecast that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current year.
Wall Street Analyst Weigh In
TMO has been the topic of a number of analyst reports. Robert W. Baird lifted their price objective on shares of Thermo Fisher Scientific from $620.00 to $632.00 and gave the company an "outperform" rating in a research report on Thursday, July 25th. Morgan Stanley increased their price target on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an "overweight" rating in a research report on Friday, September 20th. Redburn Atlantic assumed coverage on shares of Thermo Fisher Scientific in a research report on Monday. They issued a "buy" rating and a $680.00 price objective for the company. Barclays lifted their price target on Thermo Fisher Scientific from $600.00 to $620.00 and gave the company an "equal weight" rating in a report on Tuesday. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $767.00 price objective on shares of Thermo Fisher Scientific in a research note on Friday, September 20th. Four analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $656.16.
Check Out Our Latest Report on TMO
About Thermo Fisher Scientific
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Articles
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
